Article Information
History
- August 4, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Anna Basile1,
- Carla Zannella3,
- Margot De Marco1,2,
- Gianluigi Franci1,
- Massimiliano Galdiero3,
- Giuseppina Sanna4,
- Aldo Manzin4,
- Massimiliano Chetta5,
- Maria Caterina Turco1,2,
- Alessandra Rosati1,2,* and
- Liberato Marzullo1,2
- 1Department of Medicine, Surgery and Dentistry “Schola Medica Salernitana”, University of Salerno, Baronissi (SA), 84081; Italy
- 2FIBROSYS s.r.l., University of Salerno, Baronissi (SA), 84081; Italy
- 3Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, 80138; Italy
- 4Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, Monserrato, 09042; Italy
- 5U.O.C. Medical and Laboratory Genetics, A.O.R.N. Cardarelli, Naples, 80131; Italy
- ↵*Correspondence: arosati{at}unisa.it
Posted August 04, 2022.
A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells
